Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–14 of 14 results
Advanced filters: Author: Sho Iketani Clear advanced filters

  • A study reports on the antigenic characterization of SARS-CoV-2 BA.1, BA.1.1 and BA.2 and the neutralizing activity of different monoclonal antibodies and sera against them.

    • Sho Iketani
    • Lihong Liu
    • David D. Ho
    ResearchOpen Access
    Nature
    Volume: 604, P: 553-556

  • A biochemical and structural analysis demonstrates that alterations at the substrate-binding pocket of the main protease of SARS-CoV-2 can allow the virus to develop resistance to nirmatrelvir in two distinct ways.

    • Yinkai Duan
    • Hao Zhou
    • Haitao Yang
    Research
    Nature
    Volume: 622, P: 376-382

  • Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19, but viral resistance to the drug was found to arise readily via multiple pathways in vitro.

    • Sho Iketani
    • Hiroshi Mohri
    • David D. Ho
    ResearchOpen Access
    Nature
    Volume: 613, P: 558-564

  • The B.1.1.529/Omicron variant of SARS-CoV-2 is resistant to neutralization by serum not only from patients who recovered from COVID-19, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines.

    • Lihong Liu
    • Sho Iketani
    • David D. Ho
    Research
    Nature
    Volume: 602, P: 676-681

  • The SARS-CoV-2 variant B.1.1.7 can be neutralized by convalescent sera or sera from vaccinated individuals, whereas the B.1.351 variant is resistant to neutralization by these sera and by several monoclonal antibodies that are in clinical use.

    • Pengfei Wang
    • Manoj S. Nair
    • David D. Ho
    Research
    Nature
    Volume: 593, P: 130-135

  • Due to the limited efficacy of vaccines against SARS-CoV-2 and resistance to current therapies additional anti-viral therapeutics with pan-coronavirus activity are of high interest. Here, the authors screened 2.8 billion compounds from a DNA-encoded chemical library and identified small molecules that are non-covalent inhibitors targeting the conserved 3CL protease of SARS-CoV-2 and other coronaviruses.

    • Hengrui Liu
    • Arie Zask
    • Brent R. Stockwell
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-18

  • A severe acute respiratory syndrome coronavirus 2 Omicron subvariant, BA.2.86, was found to be no more resistant to human sera than the currently dominant XBB.1.5 and EG.5.1, but it had a remarkably higher receptor affinity.

    • Qian Wang
    • Yicheng Guo
    • David D. Ho
    Research
    Nature
    Volume: 624, P: 639-644

  • Findings from a systematic antigenic analysis of these surging Omicron subvariants that this lineage of SARS-CoV-2 continues to evolve, successively yielding subvariants that are not only more transmissible but also more evasive to antibodies.

    • Qian Wang
    • Yicheng Guo
    • David D. Ho
    ResearchOpen Access
    Nature
    Volume: 608, P: 603-608

  • The essential SARS-CoV-2 3CL protease is of interest as a drug target. Here, the authors identify three 3CL inhibitors and characterize them both in vitro and with a cell-based assay, and they also present the inhibitor-bound 3CL crystal structures, which may allow for the design of improved compounds.

    • Sho Iketani
    • Farhad Forouhar
    • David D. Ho
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-7

  • A member of the importin-β protein family, transportin 1, binds to influenza A virus matrix protein M1 and promotes its removal from the viral ribonucleoproteins (vRNPs), enabling disassembly of vRNP bundles, vRNP interaction with importin-α/β and entry into the nucleus.

    • Yasuyuki Miyake
    • Jeremy J. Keusch
    • Yohei Yamauchi
    Research
    Nature Microbiology
    Volume: 4, P: 578-586

  • This review paper summarizes various works on supramolecular materials with reversible and movable crosslinks and their application as adhesives. Reversible crosslinks can repeatedly associate and dissociate. Therefore, The reversible crosslinked materials show self-healing and stimuli-responsive properties. The slide of the movable crosslinks with deformation resulted in high toughness and self-relaxing of the materials. The adhesion systems with reversible and movable crosslinks show improved adhesion and cohesion properties, stability, and functionality. This new concept for designing adhesion systems is expected to enhance the lifetime of adhesives and reduce environmental problems.

    • Yunpeng Qian
    • Sho Kosaba
    • Yoshinori Takashima
    ReviewsOpen Access
    Polymer Journal
    Volume: 57, P: 491-512